Cantor Fitzgerald set a $34.00 price target on Heron Therapeutics, Inc. (NASDAQ:HRTX) in a report published on Thursday morning. The brokerage currently has a buy rating on the biotechnology company’s stock.

Other equities research analysts have also recently issued research reports about the company. JMP Securities reissued a buy rating on shares of Heron Therapeutics in a report on Wednesday, November 9th. Aegis initiated coverage on shares of Heron Therapeutics in a research report on Wednesday, October 26th. They issued a buy rating and a $41.00 price target on the stock. Brean Capital initiated coverage on shares of Heron Therapeutics in a research report on Tuesday, October 4th. They issued a buy rating and a $41.00 price target on the stock. Leerink Swann restated a buy rating and issued a $33.00 price target on shares of Heron Therapeutics in a research report on Sunday, October 2nd. Finally, Jefferies Group decreased their price target on shares of Heron Therapeutics from $46.00 to $40.00 and set a buy rating on the stock in a research report on Monday, October 3rd. One research analyst has rated the stock with a sell rating and nine have issued a buy rating to the company’s stock. The stock has an average rating of Buy and a consensus price target of $37.75.

Analyst Recommendations for Heron Therapeutics (NASDAQ:HRTX)

Shares of Heron Therapeutics (NASDAQ:HRTX) remained flat at $12.90 on Thursday. The company’s stock had a trading volume of 843,798 shares. Heron Therapeutics has a 12-month low of $12.30 and a 12-month high of $25.46. The firm’s 50 day moving average is $14.54 and its 200 day moving average is $17.06.

Heron Therapeutics (NASDAQ:HRTX) last announced its earnings results on Tuesday, November 8th. The biotechnology company reported ($1.24) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.17) by $0.07. Analysts predict that Heron Therapeutics will post ($4.51) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Heron Therapeutics, Inc. (HRTX) Given a $34.00 Price Target by Cantor Fitzgerald Analysts” was first reported by Watch List News and is the propert of of Watch List News. If you are viewing this piece on another domain, it was illegally stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this piece can be viewed at http://www.watchlistnews.com/heron-therapeutics-inc-hrtx-given-a-34-00-price-target-by-cantor-fitzgerald-analysts/1060523.html.

A number of institutional investors have recently bought and sold shares of the company. BlackRock Group LTD boosted its position in Heron Therapeutics by 9.0% in the second quarter. BlackRock Group LTD now owns 10,816 shares of the biotechnology company’s stock valued at $195,000 after buying an additional 897 shares during the last quarter. Wells Fargo & Company MN boosted its position in Heron Therapeutics by 20.0% in the third quarter. Wells Fargo & Company MN now owns 11,167 shares of the biotechnology company’s stock valued at $192,000 after buying an additional 1,858 shares during the last quarter. Parametric Portfolio Associates LLC purchased a new position in Heron Therapeutics during the second quarter valued at $213,000. BlackRock Advisors LLC boosted its position in Heron Therapeutics by 13.3% in the second quarter. BlackRock Advisors LLC now owns 15,104 shares of the biotechnology company’s stock valued at $273,000 after buying an additional 1,769 shares during the last quarter. Finally, Highbridge Capital Management LLC purchased a new position in Heron Therapeutics during the third quarter valued at $266,000.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

5 Day Chart for NASDAQ:HRTX

Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.